Cowen reaffirmed their hold rating on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a report published on Monday, AnalystRatings.com reports. The firm currently has a $13.00 price target on the specialty pharmaceutical company’s stock.
Several other analysts also recently weighed in on the company. Zacks Investment Research upgraded AMAG Pharmaceuticals from a strong sell rating to a buy rating and set a $9.25 price target on the stock in a research note on Thursday, June 20th. Barclays began coverage on AMAG Pharmaceuticals in a research note on Tuesday, June 11th. They issued an overweight rating and a $19.00 price target on the stock. ValuEngine downgraded AMAG Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, May 28th. BidaskClub downgraded AMAG Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, May 21st. Finally, SunTrust Banks set a $13.00 price target on AMAG Pharmaceuticals and gave the stock a hold rating in a research note on Tuesday, May 14th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. The company has an average rating of Hold and an average price target of $16.92.
AMAG Pharmaceuticals stock opened at $9.23 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.30 and a quick ratio of 2.13. The stock has a market cap of $311.67 million, a P/E ratio of -2.38 and a beta of 0.48. The stock has a 50 day moving average of $9.88. AMAG Pharmaceuticals has a twelve month low of $7.81 and a twelve month high of $26.10.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.77). The company had revenue of $75.80 million during the quarter, compared to analysts’ expectations of $90.13 million. AMAG Pharmaceuticals had a negative return on equity of 26.33% and a negative net margin of 30.90%. The business’s quarterly revenue was down 35.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.59) EPS. Research analysts predict that AMAG Pharmaceuticals will post -2.16 earnings per share for the current fiscal year.
In other AMAG Pharmaceuticals news, insider Elizabeth Scott Bolgiano bought 5,000 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were acquired at an average cost of $10.93 per share, for a total transaction of $54,650.00. Following the purchase, the insider now owns 74,847 shares in the company, valued at approximately $818,077.71. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO William K. Heiden bought 10,000 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were acquired at an average price of $10.70 per share, for a total transaction of $107,000.00. Following the completion of the purchase, the chief executive officer now owns 490,056 shares in the company, valued at approximately $5,243,599.20. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 25,000 shares of company stock worth $260,750. Company insiders own 4.90% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of AMAG. Pearl River Capital LLC purchased a new position in shares of AMAG Pharmaceuticals in the 4th quarter worth $28,000. NumerixS Investment Technologies Inc boosted its stake in shares of AMAG Pharmaceuticals by 17.8% in the 1st quarter. NumerixS Investment Technologies Inc now owns 7,166 shares of the specialty pharmaceutical company’s stock worth $90,000 after buying an additional 1,083 shares during the last quarter. Municipal Employees Retirement System of Michigan purchased a new position in shares of AMAG Pharmaceuticals in the 4th quarter worth $151,000. Metropolitan Life Insurance Co. NY boosted its stake in shares of AMAG Pharmaceuticals by 361.9% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,656 shares of the specialty pharmaceutical company’s stock worth $192,000 after buying an additional 9,916 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund purchased a new position in shares of AMAG Pharmaceuticals in the 4th quarter worth $200,000.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Further Reading: What economic reports are most valuable to investors?
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.